Results 51 to 60 of about 96 (70)

Real-world safety of ixekizumab: a disproportionality analysis using the FDA adverse event reporting system and the VigiAccess databases

Frontiers in Medicine
IntroductionIxekizumab is a biologic agent primarily indicated for the treatment of moderate to-severe plaque psoriasis. This study aimed to evaluate the post-marketing safety profile of ixekizumab by analyzing adverse event (AE) reports retrieved from ...
Kaidi Zhao, Xuanfeng Tan, Miao Qin, Qinxiao Li, Qinqin Meng, Ying Liu, Jing Li, Jiashu Liu   +7 more
doaj   +1 more source

Real-world study of adverse events associated with sodium zirconium cyclosilicate based on FDA adverse event reporting system and VigiAccess database.

PLoS ONE
The aim of this study was to investigate frequencies, types, and signals of adverse drug events (ADEs) associated with sodium zirconium cyclosilicate (SZC) used for the treatment of hyperkalemia, in order to inform clinicians of possible safety concerns ...
Xiaona Jia, Lei Liu, Pan Wang
doaj   +1 more source

A real-world study of ublituximab based on the WHO-VigiAccess and U.S. food and drug administration’s adverse event reporting system databases

Frontiers in Immunology
ObjectiveThe study bridge statistical pharmacovigilance signals to clinically actionable insights by systematically characterizing adverse event (AE) patterns associated with ublituximab and identifying previously unrecognized risks.
Jiagnang Cao, Qinguo Shen, Yan Zou
doaj   +1 more source

A real-world study of adverse drug reactions of two isocitrate dehydrogenase inhibitor based on the US FDA adverse event reporting system and VigiAccess databases

Frontiers in Pharmacology
Background and objectivesIsocitrate dehydrogenase (IDH) inhibitor drugs (Enasidenib, Ivosidenib) restore normal metabolism and epigenetic regulation in cells, offering a precision-targeted therapeutic option for acute myeloid leukemia (AML) patients with
Mengmeng Peng, Mengmeng Peng, Qian Guo, Zihan Dang, Baiquan Zhang, Manjuan Li, Manjuan Li, Zixuan Wang, Zixuan Wang, Xuemian Lu, Xuemian Lu, Jie Lin   +11 more
doaj   +1 more source

Safety profile of ticagrelor: an analysis based on literature and database review

BMC Cardiovascular Disorders
Objective Ticagrelor, a reversible P2Y12 receptor antagonist, is widely used in acute coronary syndromes (ACS) for its superior efficacy over clopidogrel.
Renzhu Liu, Lu Xiao, Qingzi Yan, Xiang Liu   +3 more
doaj   +1 more source

Analysis of signals for constipation among antidepressants: Using FDA adverse event reporting database [PDF]

Hospital Pharmacology
Introduction: It is estimated that 43% of patients with major depressive disorder discontinue pharmacotherapy due to adverse effects. Evidence suggests antidepressant users may experience constipation.
Kaur Milanjot, Choudhary Kunal, Janković Slobodan M.   +2 more
doaj   +1 more source

Real-world safety of aliskiren in primary hypertension: A cross-database study.

PLoS ONE
Hypertension is one of the main causes of cardiovascular diseases worldwide, affecting over one billion people. Although aliskiren offers a valuable option for inhibiting the renin-angiotensin system, its safety profile in the real world remains ...
Meirong Shan, Qian Guo, Ruofei Li, Ni Li, Yanhua Fu, Huanyu Qi, Ge Zhang, Qian Wang, Xingli Xu, Jinchuan Lai   +9 more
doaj   +1 more source

Adverse event profile of fondaparinux sodium: a disproportionality analysis based on FAERS, JADER, and VigiAccess databases

Frontiers in Medicine
BackgroundFondaparinux sodium, a synthetic pentose sugar, selectively inhibits factor Xa and is mainly used to prevent venous thromboembolism during major lower extremity orthopedic surgeries. It is also utilized for treating unstable angina pectoris and
Wei Jin, Jianwei Pan, Lin Yu, Menglu Zhu
doaj   +1 more source

Original research a real-world study of adverse events of nafamostat mesylate and sodium citrate based on the world health organization-VigiAccess database

Frontiers in Pharmacology
AimsWhile nafamostat mesylate (NM) and sodium citrate serve as commonly used extracorporeal anticoagulants in clinical practice, the characteristics and potential risks of their adverse events (AEs) need to be systematically evaluated.
Mengting Xu, Ziyi Wang, Binbin Yu
doaj   +1 more source

Post-marketing safety of tarlatamab in small cell lung cancer based on FAERS and WHO-VigiAccess with SHAP-based interpretable machine learning analysis of immune-related adverse events

Frontiers in Pharmacology
BackgroundTarlatamab is a DLL3-targeted bispecific T-cell engager approved for previously treated extensive-stage small cell lung cancer (ES-SCLC).
Yingyong Ou, Xianxian Zhong, Mei Mei, Xiao Gu, Shanshan Luo, Gaoyu Chen, Xuqin Xie, Desheng Sun   +7 more
doaj   +1 more source